Brazil approval adds a meaningful new market for acoramidis, reinforcing the drug's global commercial trajectory. Monitor H2 2026 launch execution and any upcoming regulatory decisions in additional countries. The strong Phase 3 data and multiple prior approvals de-risk this expansion, no new clinical data was required.
BBIO drugs
BBIO drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 6 $68.09entry
- T+1 · 6mo ago −0.94%α −0.61% · $67.45
- T+5 · 6mo ago −3.14%α −4.27% · $65.95
- T+20 · 6mo ago −3.83%α −6.61% · $65.48
- T+60 · 4mo ago +17.62%α +15.56% · $80.09
Price Chart
How similar events traded
Executive Summary
BridgeBio Pharma announced that Brazilian health regulator ANVISA approved acoramidis (BEYONTTRA) for ATTR-CM, adding a sixth major market to its approvals. The drug demonstrated a 42% reduction in composite all-cause mortality and recurrent cardiovascular hospitalization events versus placebo at Month 30 in the Phase 3 ATTRibute-CM study. Commercialization in Brazil, via partner Biopas, is expected to begin in H2 2026, expanding the drug's global reach beyond the U.S., EU, UK, Switzerland, and Japan.
Key Facts
- ANVISA (Brazil) approved acoramidis (BEYONTTRA) for ATTR-CM in adults.
- Approval based on Phase 3 ATTRibute-CM study showing 42% reduction in composite ACM and recurrent CVH events at Month 30 vs placebo.
- 50% reduction in cumulative frequency of CVH events at Month 30 vs placebo.
- Acoramidis is the first and only approved ATTR-CM treatment in Brazil with a label specifying near-complete (≥90%) TTR stabilization.
- Commercialization in Brazil via Biopas (Swixx BioPharma) expected to begin in H2 2026.
- Acoramidis previously approved in U.S. (Nov 2024), EU (Feb 2025), Japan (Mar 2025), UK (Apr 2025), and Switzerland.
- BridgeBio market cap ~$13.5B; analyst consensus 97% bullish (29 of 30 analysts Buy/Strong Buy).
Financial Impact
Expands total addressable market for acoramidis to Brazil, the largest Latin American pharmaceutical market. No specific revenue guidance provided; prior U.S. approval in Nov 2024 and EU/Japan approvals in early 2025 already established commercial base.
Risk Factors
- Commercialization in Brazil depends on partner Biopas execution; any delays in H2 2026 launch could disappoint.
- Pricing and reimbursement negotiations in Brazil may limit initial uptake.
- Competition from Pfizer's tafamidis (Vyndamax) and other emerging ATTR-CM therapies in the Brazilian market.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3288693 |
Track record
38 reports on BBIO
10 of 12 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 13 of 14 went positive at some point.
Filters
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $78.30 +0.17% settles Dec 11
- Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
- Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $78.30 +4.47% settles Nov 30
- Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $78.30 +10.56% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $78.30 +14.94% settles Nov 19
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $78.30 +23.70% ▲ +24.28% +27.89% vs SPY
- Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers